Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Blood (2022) 140 (8): 839–850.

https://doi.org/10.1182/blood.2021015014

Published: 2022

Includes: Supplemental data

Journal Articles

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Paolo Ghia, Viktor Ljungström, Eugen Tausch, Andreas Agathangelidis, Annika Scheffold, Lydia Scarfo, Billy Michael Chelliah Jebaraj, Carolyn J. Owen, MD MDes(UK), FRCPC, Jacqueline C. Barrientos, MD, Marc Zapatka, Veerendra Munugalavadla, Jeremiah D. Degenhardt, Yeonhee Kim, Ronald L. Dubowy, Lyndah K. Dreiling, Richard Rosenquist, Stephan Stilgenbauer

Blood (2016) 128 (22): 2770.

https://doi.org/10.1182/blood.V128.22.2770.2770

Published: 2016

Journal Articles

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Amy M Trottier, MD MSc, Adnan Mansoor, MD FRCPC, Carolyn J. Owen, MD MDes(UK), FRCPC, Ariz Akhter, PhD, Etienne Mahe, BSc, MD FRCPC, Michelle Geddes, MD FRCPC

Blood (2016) 128 (22): 1683.

https://doi.org/10.1182/blood.V128.22.1683.1683

Published: 2016

Journal Articles

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Robert E Marcus, Andrew J Davies, FRCP PhD, Kiyoshi Ando, Wolfram Klapper, MD, Stephen Opat, MD, Carolyn J Owen, Elizabeth H Phillips, Randeep Sangha, Rudolf Schlag, John F Seymour, William Townsend, Marek Trněný, Michael K Wenger, Günter Fingerle-Rowson, Kaspar Rufibach, Tom Moore, Michael Herold, Wolfgang Hiddemann, MD

Blood (2016) 128 (22): 6.

https://doi.org/10.1182/blood.V128.22.6.6

Published: 2016

Journal Articles

Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations

Anna L Brown, PhD, Christopher N Hahn, PhD, Catherine Carmichael, Ella Wilkins, Milena Babic, BMPharBio (Hons), Chan-Eng Chong, PhD, Xiao-Chun Li, Joelle Michaud, Ping Cannon, Nicola Poplawski, MBChB, DipPaed, FRACP, MD, Meryl Altree, Kerry Phillips, Louise Jaensch, Miriam Fine, Andreas W Schreiber, PhD, Jinghua Feng, PhD, Lesley Rawlings, PhD, Cassandra Vakulin, Carolyn Butcher, Richard D'Andrea, PhD, Ian D Lewis, MBBS, PhD FRACP, FRCPA, Nigel Patton, Cecily Forsyth, MBBS, FRACP, FRCPA, Sally Mapp, PhD MD, Helen Mar Fan, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Julian Cooney, MD, Mark S Currie, MD, Uday R. Popat, MD, Kenneth Bradstock, MBBS, PhD, April D. Sorrell, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Marshall S Horwitz, MD PhD, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Alwin Krämer, MD, Stefan Fröhling, MD, Lucy A Godley, MD PhD, Jane E Churpek, MD, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS

Blood (2016) 128 (22): 1212.

https://doi.org/10.1182/blood.V128.22.1212.1212

Published: 2016

Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Blood (2016) 128 (22): 234.

https://doi.org/10.1182/blood.V128.22.234.234

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Blood (2016) 128 (22): 2054.

https://doi.org/10.1182/blood.V128.22.2054.2054

Published: 2016

Journal Articles

CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD)

Ryan J. Stubbins, MD BSc, James Zhu, BSc, MD, Raymond Lai, MD PhD, Carolyn J. Owen, MD MDes(UK), FRCPC, Jutta Preiksaitis, MD FRCPC, Anthea C Peters, MD M.Sc., FRCPC

Blood (2016) 128 (22): 1873.

https://doi.org/10.1182/blood.V128.22.1873.1873

Published: 2016

Journal Articles

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Jeffrey P. Sharman, Gilles A. Salles, Wojciech Jurczak, Jeffrey Jones, Carolyn J. Owen, MD MDes(UK), FRCPC, Veerendra Munugalavadla, Lyndah K. Dreiling, Yuanyuan Xiao, Arati V. Rao, Ian W. Flinn, MD PhD, Susan M. O'Brien, MD

Blood (2016) 128 (22): 5583.

https://doi.org/10.1182/blood.V128.22.5583.5583

Published: 2016

Journal Articles

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Joanna Graczyk, MD FRCPC, Sunita Ghosh, PhD, Neil Chua, MD FRCPC, Douglas A. Stewart, MD FRCPC, Carolyn J. Owen, MD FRCPC

Blood (2014) 124 (21): 2520.

https://doi.org/10.1182/blood.V124.21.2520.2520

Published: 2014

Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Blood (2013) 122 (21): 6.

https://doi.org/10.1182/blood.V122.21.6.6

Published: 2013

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

Journal Articles

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Lesley E. Street, MD, FRCPC, Nizar J. Bahlis, MD, Karen Valentine, MD, PhD, Deirdre A. Jenkins, MD, FRCPC, Carolyn J Owen, MD, FRCPC, Mona Shafey, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCPC

Blood (2012) 120 (21): 2003.

https://doi.org/10.1182/blood.V120.21.2003.2003

Published: 2012

Journal Articles

Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era

Anthea Peters, MD, MSc, FRCPC, Carolyn J Owen, MD, FRCPC, Karen Doucette, MD, FRCPC, Jutta Preiksaitis, MD, FRCPC

Blood (2011) 118 (21): 1645.

https://doi.org/10.1182/blood.V118.21.1645.1645

Published: 2011

Journal Articles

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Paola Neri, MD, PhD, Li Ren, PhD, Jordan Johnson, Kathy J Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 1834.

https://doi.org/10.1182/blood.V118.21.1834.1834

Published: 2011

Journal Articles

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Paola Neri, MD, PhD, Li Ren, PhD, Kathy Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar J Bahlis, MD

Blood (2010) 116 (21): 789.

https://doi.org/10.1182/blood.V116.21.789.789

Published: 2010

Journal Articles

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Nizar J Bahlis, MD, Carolyn J Owen, MD, FRCPC, Paola Neri, MD, PhD, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Kathy J Gratton, Peter Duggan, MD, FRCPC, Pietro Ravani, MD, PhD, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 324.

https://doi.org/10.1182/blood.V116.21.324.324

Published: 2010

Journal Articles

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Carolyn J Owen, MD, FRCPC, Andrew Daly, MD, FRCPC, Neil Chua, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 1346.

https://doi.org/10.1182/blood.V116.21.1346.1346

Published: 2010

Journal Articles

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Carolyn J. Owen, Cynthia L. Toze, Anna Koochin, Donna L. Forrest, Clayton A. Smith, Jane M. Stevens, Shannon C. Jackson, Man-Chiu Poon, Gary D. Sinclair, Brian Leber, Peter R. E. Johnson, Anthony Macheta, John A. L. Yin, Michael J. Barnett, T. Andrew Lister, Jude Fitzgibbon

Blood (2008) 112 (12): 4639–4645.

https://doi.org/10.1182/blood-2008-05-156745

Published: 2008

Includes: Supplemental data

Journal Articles

Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML)

Carolyn J Owen, Cynthia L Toze, Anna Koochin, Donna L. Forrest, Clayton A. Smith, Shannon C Jackson, Man-Chiu Poon, Gary D. Sinclair, Brian Leber, Peter Johnson, Anthony Macheta, John AL Yin, Michael J. Barnett, T. Andrew Lister, Jude Fitzgibbon

Blood (2008) 112 (11): 5067.

https://doi.org/10.1182/blood.V112.11.5067.5067

Published: 2008

NARROW

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

Whole-Exome Sequencing Revealed No Recurrent Mutations within the PI3K Pathway in Relapsed Chronic Lymphocytic Leukemia Patients Progressing Under Idelalisib Treatment

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study

Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD)

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Population Based Analysis of Outcomes of Primary Central Nervous System Lymphoma (PCNSL) Suggests a Treatment Strategy Including Intensive Chemotherapy with Autologous Stem Cell Transplantation Provides a Survival Advantage for Patients <65 Years of Age

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada

Lymphopenia and EBER-Negativity Predict Poor Survival in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD) Treated in the Rituximab Era

Bortezomib Impairs Myeloma Cells (MM) Homologous Recombination Through Inhibition of the E2-Ubiquitin-Conjugating Enzyme UBC13

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Population-Based Study of the Outcomes of Primary Central Nervous System Lymphoma (PCNSL) In the Era of Autologous Stem Cell Transplantation (ASCT)

Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Five New Pedigrees with Inherited RUNX1 Mutations Causing Familial Platelet Disorder with Propensity to Myeloid Malignancy (FPD/AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only